Hepagam B - NDC Database

14 records found
Page:1
49591-051 Dec 01, 2023
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Kamada Ltd.
49591-052 Dec 01, 2023
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Kamada Ltd.
53270-0051 Aug 01, 2010
Hepagam B 312 [iu]/Ml Intramuscular; Intravenous Injection, Solution by Cangene Biopharma Inc.
53270-0052 Aug 01, 2010
Hepagam B 312 [iu]/Ml Intramuscular; Intravenous Injection, Solution by Cangene Biopharma Inc.
53270-0053 Aug 01, 2010
Hepagam B 50 mg/ml Intramuscular; Intravenous Injection, Solution by Cangene Biopharma Inc.
53270-0054 Aug 01, 2010
Hepagam B 50 mg/ml Intramuscular; Intravenous Injection, Solution by Cangene Biopharma Inc.
70257-051 Mar 01, 2019
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection by Saol Therapeutics Inc.
70257-052 Mar 01, 2019
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection by Saol Therapeutics Inc.
70257-053 Jun 20, 2018
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection by Saol Therapeutics Inc.
70257-054 Jun 20, 2018
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection by Saol Therapeutics Inc.
70504-0051 Jul 01, 2016
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Aptevo Biotherapeutics LLC
70504-0052 Jul 01, 2016
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Injection, Solution by Aptevo Biotherapeutics LLC
70504-0053 Jul 01, 2016
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Solution by Aptevo Biotherapeutics LLC
70504-0054 Jul 01, 2016
Hepagam B 312 [Iu]/Ml Intramuscular; Intravenous Solution by Aptevo Biotherapeutics LLC
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.